New app aims to prevent dangerous blood sugar dips during workouts for type 1 diabetes

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Inclusion Criteria: All Participants (Type 1 Diabetes and Healthy Control Groups) * Adults between the age of 18-60 years * Able to perform moderate intensity walking for 60 minutes (target 40-60% age-predicted maximal heart rate). * Willing and able to comply with study procedures, including supervised exercise visits and device wear * Able to provide written informed consent Inclusion Criteria: Type 1 Diabetes Group Only * Clinical diagnosis of type 1 diabetes for \>1 year, based on the investigator's clinical judgement * Current use of continuous subcutaneous insulin infusion with Tandem Control-IQ and a compatible continuous glucose monitor (CGM) for \>1 month prior to enrollment * Stable insulin delivery regimen, with no planned changes to insulin pump settings or insulin dosing strategy during the study period * Consistent CGM use during the month prior to enrollment (\>80% data availability) Inclusion Criteria: Health Control Group Only * No diagnosis of diabetes or other disorders of glucose metabolism * Not using insulin or glucose-lowering medications Exclusion Criteria Exclusion Criteria: All Participants * Intercurrent illness or medical condition that precludes safe participation in moderate-intensity exercise (e.g., unstable cardiopulmonary disease, uncontrolled arrhythmia, or uncontrolled hypertension), as previously assessed by the participant's primary care physician * Known coronary artery disease with symptoms limiting moderate physical activity, or history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the past 12 months * Pregnancy, lactation, or plans to become pregnant during the study period * Renal insufficiency with estimated GFR \<45 mL/min/1.73 m², dialysis dependence, or adrenal insufficiency * Concurrent participation in another interventional drug or device study within 30 days prior to enrollment * Inability to comply with study procedures or safety requirements (e.g., inability to achieve target heart-rate zone, attend scheduled visits, or enable required device data access), or otherwise deemed unsuitable by the investigator Exclusion Criteria: Type 1 Diabetes Group Only * Use of non-CSII insulin delivery, including long-acting injectable or inhaled insulin, during the study period * Use of medications with potential to substantially affect glycemia (e.g., SGLT-2 inhibitors, GLP-1 receptor agonists, or GIP agonists), unless on a stable regimen with no planned changes during the study * Use of systemic corticosteroids within 4 weeks prior to participation * History of severe hypoglycemia (requiring third-party assistance) or diabetic ketoacidosis within the prior 6 months